HTA155 The Impact of Phase 2 Clinical Trials on Reimbursement Recommendations in Oncology By Canadian Health Technology Assessment Agencies
Abstract
Authors
M. Ham M. Pelletier K. Guinan A. Gosselin N. Paul Roc S. Barakat C. Beauchemin